CLRB
Cellectar Biosciences INC NEW
stockNASDAQ
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.83 | 2026-09-28 | -1.64% | -5.207 |
| 1M | 2.37 | 2026-09-04 | -24.05% | -1.231 |
| 3M | 2.77 | 2026-07-06 | -35.02% | 0.256 |
| 6M | 2.71 | 2026-04-06 | -33.58% | 1.495 |
| 1Y | 5.78 | 2025-10-03 | -68.86% | 1.476 |
| 2Y | 66.00 | 2024-10-04 | -97.27% | — |
| 5Y | 259.50 | 2021-10-04 | -99.31% | 1.141 |
Cellectar Biosciences INC NEW (NASDAQ:CLRB) stock price today is $1.80, and today's volume is 48,040. CLRB is down 3.743% today. The 30 day average volume is 51,264. CLRB market cap is $17.01M with 9.45M shares outstanding.